Investors Alerted to Deadline in Outlook Therapeutics, Inc. Class Action Lawsuit

LOS ANGELES, Nov 20, 2023 (GLOBE NEWSWIRE) – Investors who acquired shares of Outlook Therapeutics, Inc. OTLK, a biopharmaceutical company specializing in monoclonal antibody development for eye diseases, have been alerted by Glancy Prongay & Murray LLP ('GPM') about an important approaching deadline. The legal firm has reminded shareholders that January 2, 2024 is the final day for potential lead plaintiffs to file their motions in the class action suit against Outlook Therapeutics. This litigation concerns those who purchased or otherwise obtained OTLK securities and have been affected by alleged corporate misconduct.

Understanding the Class Action

The class action lawsuit against Outlook Therapeutics alleges that the company may have provided misleading information or failed to disclose pertinent information that could impact investors' decisions. The lawsuit seeks to recover damages on behalf of the class of investors under federal securities laws. As deadlines approach, GPM stresses the importance for investors to act promptly if they wish to serve as a lead plaintiff, which comes with certain responsibilities and powers in representing the class.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is based in Cranbury, New Jersey, focusing on groundbreaking treatments within the realm of ophthalmology. The company aims to provide innovative solutions for patients suffering from eye diseases. Despite its objectives, the current legal situation poses questions for shareholders and potential investors regarding the direction and handling of information by the company's management.

Investor Participation

Investors of OTLK who have been affected by the allegations have a limited window to apply for the position of lead plaintiff. Should they miss the January 2, 2024 deadline, they may forfeit certain legal rights and their ability to influence the lawsuit's proceedings. Shareholders who have significant losses and wish to take a more active role in the litigation are encouraged to consider lead plaintiff status. GPM urges affected shareholders to contact the firm for more details concerning their rights and options.

deadline, lawsuit, investors